STUDY OBJECTIVES: To determine the effects of the nonbenzodiazepine sedative zopiclone on the threshold to arousal with increasing respiratory effort and genioglossus muscle activity and to examine potential physiological factors mediating disparate effects of zopiclone on obstructive sleep apnea (OSA) severity between patients. METHODS:Twelve patients with OSA (apnea-hypopnea index = 41 ± 8 events/h) were studied during 2 single night sleep studies conducted approximately 1 w apart after receiving 7.5 mg of zopiclone or placebo according to a double-blind, placebo-controlled, randomized, crossover design. The respiratory arousal threshold (epiglottic pressure immediately prior to arousal during naturally occurring respiratory events), genioglossus activity and its responsiveness to pharyngeal pressure during respiratory events, and markers of OSA severity were compared between conditions. Genioglossus movement patterns and upper airway anatomy were also assessed via magnetic resonance imaging in a subset of participants (n = 7) during wakefulness. RESULTS:Zopiclone increased the respiratory arousal threshold versus placebo (-31.8 ± 5.6 versus -26.4 ± 4.6 cmH2O, P = 0.02) without impairing genioglossus muscle activity or its responsiveness to negative pharyngeal pressure during respiratory events (-0.56 ± 0.2 versus -0.44 ± 0.1 %max/-cmH2O, P = 0.48). There was substantial interindividual variability in the changes in OSA severity with zopiclone explained, at least in part, by differences in pathophysiological characteristics including body mass index, arousal threshold, and genioglossus movement patterns. CONCLUSIONS: In a group of patients with predominantly severe OSA, zopiclone increased the arousal threshold without reducing genioglossus muscle activity or its responsiveness to negative pharyngeal pressure. These properties may be beneficial in some patients with OSA with certain pathophysiological characteristics but may worsen hypoxemia in others. CLINICAL TRIAL REGISTRATION: Australian New Zealand Clinical Trials Registry, http://www.anzctr.org.au, trial ID: ACTRN12614000364673.
RCT Entities:
STUDY OBJECTIVES: To determine the effects of the nonbenzodiazepine sedative zopiclone on the threshold to arousal with increasing respiratory effort and genioglossus muscle activity and to examine potential physiological factors mediating disparate effects of zopiclone on obstructive sleep apnea (OSA) severity between patients. METHODS: Twelve patients with OSA (apnea-hypopnea index = 41 ± 8 events/h) were studied during 2 single night sleep studies conducted approximately 1 w apart after receiving 7.5 mg of zopiclone or placebo according to a double-blind, placebo-controlled, randomized, crossover design. The respiratory arousal threshold (epiglottic pressure immediately prior to arousal during naturally occurring respiratory events), genioglossus activity and its responsiveness to pharyngeal pressure during respiratory events, and markers of OSA severity were compared between conditions. Genioglossus movement patterns and upper airway anatomy were also assessed via magnetic resonance imaging in a subset of participants (n = 7) during wakefulness. RESULTS:Zopiclone increased the respiratory arousal threshold versus placebo (-31.8 ± 5.6 versus -26.4 ± 4.6 cmH2O, P = 0.02) without impairing genioglossus muscle activity or its responsiveness to negative pharyngeal pressure during respiratory events (-0.56 ± 0.2 versus -0.44 ± 0.1 %max/-cmH2O, P = 0.48). There was substantial interindividual variability in the changes in OSA severity with zopiclone explained, at least in part, by differences in pathophysiological characteristics including body mass index, arousal threshold, and genioglossus movement patterns. CONCLUSIONS: In a group of patients with predominantly severe OSA, zopiclone increased the arousal threshold without reducing genioglossus muscle activity or its responsiveness to negative pharyngeal pressure. These properties may be beneficial in some patients with OSA with certain pathophysiological characteristics but may worsen hypoxemia in others. CLINICAL TRIAL REGISTRATION: Australian New Zealand Clinical Trials Registry, http://www.anzctr.org.au, trial ID: ACTRN12614000364673.
Authors: Robert B Fogel; John Trinder; David P White; Atul Malhotra; Jill Raneri; Karen Schory; Darci Kleverlaan; Robert J Pierce Journal: J Physiol Date: 2005-02-03 Impact factor: 5.182
Authors: Julia Boyle; John A Groeger; Walter Paska; James A Cooper; Carol Rockett; Sion Jones; Paul Gandhi; Jenny Scott; Giuseppe Atzori; Derk-Jan Dijk Journal: J Clin Psychopharmacol Date: 2012-10 Impact factor: 3.153
Authors: Danny J Eckert; David P White; Amy S Jordan; Atul Malhotra; Andrew Wellman Journal: Am J Respir Crit Care Med Date: 2013-10-15 Impact factor: 21.405
Authors: Elizabeth C Brown; Shaokoon Cheng; David K McKenzie; Jane E Butler; Simon C Gandevia; Lynne E Bilston Journal: Sleep Date: 2013-07-01 Impact factor: 5.849
Authors: Nirupama S Wijesuriya; Laura Gainche; Amy S Jordan; David J Berlowitz; Mariannick LeGuen; Peter D Rochford; Fergal J O'Donoghue; Warren R Ruehland; Jayne C Carberry; Jane E Butler; Danny J Eckert Journal: J Physiol Date: 2018-04-25 Impact factor: 5.182
Authors: Diego R Mazzotti; Diane C Lim; Kate Sutherland; Lia Bittencourt; Jesse W Mindel; Ulysses Magalang; Allan I Pack; Philip de Chazal; Thomas Penzel Journal: Physiol Meas Date: 2018-09-13 Impact factor: 2.833
Authors: Jason Amatoury; Amy S Jordan; Barbara Toson; Chinh Nguyen; Andrew Wellman; Danny J Eckert Journal: Sleep Date: 2018-11-01 Impact factor: 5.849
Authors: Luigi Taranto-Montemurro; Scott A Sands; Bradley A Edwards; Ali Azarbarzin; Melania Marques; Camila de Melo; Danny J Eckert; David P White; Andrew Wellman Journal: Sleep Date: 2017-02-01 Impact factor: 5.849
Authors: Lucas M Donovan; Aditi Shah; Ching Li Chai-Coetzer; Ferran Barbé; Najib T Ayas; Vishesh K Kapur Journal: Chest Date: 2019-10-19 Impact factor: 9.410
Authors: Cathy A Goldstein; Richard B Berry; David T Kent; David A Kristo; Azizi A Seixas; Susan Redline; M Brandon Westover Journal: J Clin Sleep Med Date: 2020-04-15 Impact factor: 4.062